Advertisement

Search Results for "Keppra And Fasciculations"

22:46 EDT 18th May 2013 | BioPortfolio

Original Source: Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease

Levetiracetam (Keppra) is used to treat partial onset seizures. Its biological effects suggest it might also be useful in treating 3 aspects of human motor neuron diseases (MNDs) for which no effective therapy exists: cramps, spasticity, and disease progression.

Matching Channels

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

Matching News

FDA Approves Generic Keppra XR Tablets

Qualitest Pharmaceuticals today announced that it has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Levetiracetam extended-release tablets, 500mg and 750mg, the ge...

UCB Seeks Japan Approval For Pediatric Use Of Keppra And First-ever Dry Syrup Form

Otsuka Pharmaceuticals and UCB Japan announced on June 21 that UCB applied for approval of adding pediatric epilepsy to the applicable uses of E Keppra (levetiracetam).

UCB plots post-keppra growth path following strong 2012

The Belgian CNS/immunology-focused firm UCB saw sales of its trio of new growth drivers exceed those of its one-time cash cow, the epilepsy medicine Keppra, for the first time last year. With total...

UCB propels Vimpat monotherapy along Keppra path, but can it beat Keppra?

UCB has reported positive Phase III data that shows that its anti-epileptic drug, lacosamide (Vimpat) performs better when used as monotherapy than when used an adjunct. This data, the company said, w...

Intellipharmaceutics Announces Update on Its Generic Versions of Keppra XR(R) and Pristiq(R)

TORONTO, March 13, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...

Intellipharmaceutics Achieves a 2012 Goal by Filing Two ANDAs -- Generic Forms of Keppra XR(R) and Pristiq(R)

TORONTO, Sept. 5, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel a...

Human medicines European Public Assessment Report (EPAR): Keppra, levetiracetam, Revision: 28, Authorised

Human medicines European Public Assessment Report (EPAR): Keppra, levetiracetam, Revision: 27, Authorised

Matching PubMed Articles

Fasciculations and cramps: how benign? Report of four cases progressing to ALS.

Clinical diagnosis of amyotrophic lateral sclerosis (ALS) in patients presenting with cramps and fasciculations may not be evident at the first consultation. Sequential reviews, clinical and neurophys...

Fasciculation anxiety syndrome in clinicians.

The goal of this study is to define the clinical features, pathogenesis and key investigation findings of fasciculation anxiety syndrome in clinicians (FASICS). Twenty consecutive clinicians presentin...

Ultrasonographic Detection of Fasciculations Markedly Increases Diagnostic Sensitivity of ALS.

Teaching NeuroImages: Somatic muscle fasciculations detected by electrocardiography.

Muscle changes in amyotrophic lateral sclerosis: A longitudinal ultrasonography study.

OBJECTIVE: We performed a longitudinal study to assess structural muscle changes in amyotrophic lateral sclerosis (ALS) using ultrasonography. METHODS: During a follow-up of 6months, ultrasonography p...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement